139 related articles for article (PubMed ID: 31328140)
1. Perfusion Magnetic Resonance as a Biomarker for Sorafenib-Treated Advanced Hepatocellular Carcinoma: A Pilot Study.
Campos M; Candelária I; Papanikolaou N; Simão A; Ferreira C; Manikis GC; Caseiro-Alves F
GE Port J Gastroenterol; 2019 Jul; 26(4):260-267. PubMed ID: 31328140
[TBL] [Abstract][Full Text] [Related]
2. Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy.
Sahani DV; Jiang T; Hayano K; Duda DG; Catalano OA; Ancukiewicz M; Jain RK; Zhu AX
J Hematol Oncol; 2013 Jul; 6():51. PubMed ID: 23842041
[TBL] [Abstract][Full Text] [Related]
3. Dual-input two-compartment pharmacokinetic model of dynamic contrast-enhanced magnetic resonance imaging in hepatocellular carcinoma.
Yang JF; Zhao ZH; Zhang Y; Zhao L; Yang LM; Zhang MM; Wang BY; Wang T; Lu BC
World J Gastroenterol; 2016 Apr; 22(13):3652-62. PubMed ID: 27053857
[TBL] [Abstract][Full Text] [Related]
4. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST).
Jiang T; Kambadakone A; Kulkarni NM; Zhu AX; Sahani DV
Invest Radiol; 2012 Jan; 47(1):11-7. PubMed ID: 21512396
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of Dynamic Contrast-Enhanced MRI-Derived Pharmacokinetic Variables in Glioblastoma Patients: Analysis of Contrast-Enhancing Lesions and Non-Enhancing T2 High-Signal Intensity Lesions.
Kang Y; Hong EK; Rhim JH; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SW; Choi SH
Korean J Radiol; 2020 Jun; 21(6):707-716. PubMed ID: 32410409
[TBL] [Abstract][Full Text] [Related]
6. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
[TBL] [Abstract][Full Text] [Related]
7. Liver stiffness in magnetic resonance elastography is prognostic for sorafenib-treated advanced hepatocellular carcinoma.
Kim B; Kim SS; Cho SW; Cheong JY; Huh J; Kim JK; Lee JH; Ahn HR; Cho HJ
Eur Radiol; 2021 Apr; 31(4):2507-2517. PubMed ID: 33033862
[TBL] [Abstract][Full Text] [Related]
8. DCE-MRI for Early Prediction of Response in Hepatocellular Carcinoma after TACE and Sorafenib Therapy: A Pilot Study.
Saito K; Ledsam J; Sugimoto K; Sourbron S; Araki Y; Tokuuye K
J Belg Soc Radiol; 2018 Apr; 102(1):40. PubMed ID: 30039052
[TBL] [Abstract][Full Text] [Related]
9. Comparison of dynamic contrast-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for evaluation of the effects of sorafenib in a rat model of hepatocellular carcinoma.
Muñoz NM; Minhaj AA; Maldonado KL; Kingsley CV; Cortes AC; Taghavi H; Polak U; Mitchell JM; Ensor JE; Bankson JA; Rashid A; Avritscher R
Magn Reson Imaging; 2019 Apr; 57():156-164. PubMed ID: 30465870
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
[TBL] [Abstract][Full Text] [Related]
11. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
[TBL] [Abstract][Full Text] [Related]
12. Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma.
Chen BB; Hsu CY; Yu CW; Liang PC; Hsu C; Hsu CH; Cheng AL; Shih TT
Eur Radiol; 2017 Jul; 27(7):3069-3079. PubMed ID: 27957638
[TBL] [Abstract][Full Text] [Related]
13. Pilot study on evaluation of any correlation between MR perfusion (Ktrans) and diffusion (apparent diffusion coefficient) parameters in brain tumors at 3 Tesla.
Chu JP; Mak HK; Yau KK; Zhang L; Tsang J; Chan Q; Ka-Kit Leung G
Cancer Imaging; 2012 Jan; 12(1):1-6. PubMed ID: 22275724
[TBL] [Abstract][Full Text] [Related]
14. The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management.
Faloppi L; Scartozzi M; Bianconi M; Svegliati Baroni G; Toniutto P; Giampieri R; Del Prete M; De Minicis S; Bitetto D; Loretelli C; D'Anzeo M; Benedetti A; Cascinu S
BMC Cancer; 2014 Feb; 14():110. PubMed ID: 24552144
[TBL] [Abstract][Full Text] [Related]
15. Dynamic contrast enhanced perfusion CT imaging: A diagnostic biomarker tool for survival prediction of tumour response to antiangiogenetic treatment in patients with advanced HCC lesions.
Ippolito D; Querques G; Okolicsanyi S; Talei Franzesi C; Pecorelli A; Lombardi S; Orsini E; Strazzabosco M; Sironi S
Eur J Radiol; 2018 Sep; 106():62-68. PubMed ID: 30150052
[TBL] [Abstract][Full Text] [Related]
16. A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma.
Mahalingam D; Peguero J; Cen P; Arora SP; Sarantopoulos J; Rowe J; Allgood V; Tubb B; Campos L
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31212948
[No Abstract] [Full Text] [Related]
17. Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib.
Hong YM; Yoon KT; Hwang TH; Heo J; Woo HY; Cho M
Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1250-1255. PubMed ID: 30925530
[TBL] [Abstract][Full Text] [Related]
18. Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II Trials.
Chen BB; Lin ZZ; Shao YY; Hsu C; Hsu CH; Cheng AL; Liang PC; Shih TT
Cancers (Basel); 2021 Oct; 13(19):. PubMed ID: 34638446
[TBL] [Abstract][Full Text] [Related]
19. Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound.
Zocco MA; Garcovich M; Lupascu A; Di Stasio E; Roccarina D; Annicchiarico BE; Riccardi L; Ainora ME; Ponziani F; Caracciolo G; Rapaccini GL; Landolfi R; Siciliano M; Pompili M; Gasbarrini A
J Hepatol; 2013 Nov; 59(5):1014-21. PubMed ID: 23811306
[TBL] [Abstract][Full Text] [Related]
20. Magnetic resonance imaging-based tumour perfusion parameters are biomarkers predicting response after radiation to brain metastases.
Jakubovic R; Sahgal A; Soliman H; Milwid R; Zhang L; Eilaghi A; Aviv RI
Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):704-12. PubMed ID: 25023291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
